- The U.S. FDA has approved a single, once monthly maintenance dose of Eli Lilly’s (NYSE:LLY) Omvoh (mirikizumab) given subcutaneously for ulcerative colitis.
- Although a monthly subcutaneous dose was already approved in this indication, it required two consecutive 100 mg injections. The new
Lilly gains approval of single monthly dose of Omvoh for ulcerative colitis
